A Phase 2a trial of ANB020 in patients with severe adult eosinophilic asthma.
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2017
At a glance
- Drugs ANB 020 (Primary)
- Indications Asthma
- Focus Therapeutic Use
- 07 Nov 2017 According to an AnaptysBio media release, top-line data from this trial are expected in the second quarter of 2018.
- 10 Oct 2017 Status changed from planning to recruiting according to an AnaptysBio media release.
- 10 Aug 2017 According to an AnaptysBio media release, the company received clearance from the U.K. Medicines & Healthcare products Regulatory Agency to proceed this phase 2a trial in 24 adult patients with severe eosinophilic asthma